Bob Bradway, Chairman and CEO of Amgen, shares groundbreaking phase three results for Repatha, showing promise in heart-attack prevention, and introduces Meritide, a potential game-changer for obesity and diabetes. Meanwhile, Dr. Alan Baratz, CEO of D-Wave Quantum, discusses the rapid commercial adoption of their quantum systems, highlighting major clients like Japan Tobacco. Baratz also delves into the technical innovations behind D-Wave's offerings and the competitive landscape in quantum computing.
